By Kim Han-joo
SEOUL, Feb. 14 (Yonhap) -- Sales of the biosimilar Remsima by Celltrion Inc. reached an all-time high last year in the United States, the company said Monday.
Sales of the biosimilar drug to treat autoimmune diseases jumped 13 percent on-year to US$385 million in 2021, Celltrion Healthcare said, citing industry data.
Remsima references Janssen Biotech Inc.'s Remicade and is effective in treating various diseases, from rheumatoid arthritis to Crohn's disease.
Pharmaceutical giant Pfizer Inc. is responsible for sales of the biosimilar drug under the name Inflectra in the U.S. market.
Remsima's market shares in the U.S. came to 22.3 percent, trailing Remicade with 67.2 percent during the fourth quarter of last year, according to Celltrion Healthcare.
Sales of Remicade nearly halved over the last five years, plummeting from $4.5 billion in 2017 to $2 billion in 2021 following the launch of Remsima in the fourth quarter of 2016.
Yoon's outreach to Southeast Asia keeps China in the loop
Allies' defense chiefs highlight watertight alliance based on full extended deterrence against N. Korean threats
(News Focus) Police under fire for lax response to emergency calls hours before Itaewon crush
Police under fire for lax response to emergency calls hours before Itaewon crush
Role of administrative authorities questioned in Itaewon disaster